Allarity Therapeutics, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Investigation Details

Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning “the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the “FDA”) regarding the Company’s NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.” On this news, the price of the Company’s stock dropped.